Cellectar Biosciences, Inc. | 2013 | FY | 3


The following table summarizes information with regard to outstanding warrants to purchase common stock as of December 31, 2013.
 
Offering
 
Number of Shares
Issuable Upon 
Exercise of 
 Outstanding  
Warrants
 
Exercise 
 Price
 
Expiration Date
 
 
 
 
 
 
 
 
 
 
February 2013 Public Offering (1)
 
11,000,000
 
$
0.50
 
February 20, 2018
 
February 2013 Public Offering (1) (2)
 
5,500,000
 
$
0.50
 
February 20, 2014
 
February 2013 Public Offering – Placement Agents
 
770,000
 
$
0.625
 
February 4, 2018
 
November 2012 Private Placement
 
1,000,000
 
$
1.25
 
November 2, 2017
 
June 2012 Public Offering
 
2,981,440
 
$
1.25
 
June 13, 2017
 
December 2011 Underwritten Offering
 
9,248,334
 
$
0.60
 
December 6, 2016
 
April 2011 Private Placement
 
6,058,811
 
$
0.75
 
March 31, 2016
 
Legacy warrants (1)
 
27,310
 
$
0.50
 
July 27, 2015
 
Legacy warrants
 
105,040
 
$
16.065
 
July 27, 2015
 
Legacy warrants
 
91,524
 
$
99.45-100.98
 
December 31, 2015
 
 
 
 
 
 
 
 
 
 
Total
 
36,782,459
 
 
 
 
 
 
 
 
(1)
The exercise prices of these warrants are subject to adjustment for “down-rounds” and the warrants have been accounted for as derivative instruments as described in Note 3.
(2)
On February 20, 2014, warrants to purchase 5,500,000 shares of common stock expired unexercised (see Note 17).

us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock